Among patients with MO at baseline, the placebo-adjusted LS mean (95% confidence interval [CI]) change from baseline in the monthly average number of headache days of at least moderate severity during the 12-week treatment period was significantly greater with fremanezumab quarterly (− 2.2 [− 3.1 to − 1.2]; P < 0.0001) and monthly (− 2.7 [− 3.7 to − 1.8]; P < 0.0001) (Fig. 1a). Similar results were seen in patients without MO at baseline (quarterly − 1.4 [− 2.3 to − 0.5], P = 0.0026; monthly − 1.4 [− 2.3 to − 0.6], P = 0.0017 vs placebo) (Fig. 1a). Fremanezumab-treated patients with MO had numerically greater reductions in the monthly average number of headache days of at least moderate severity than patients without MO and demonstrated a larger treatment effect over placebo than those with MO.
Fig. 1 Change in days with (a) headache, (b) migraine, and (c) medication use in patients with CM by MO. Values shown are the mean changes from baseline in the monthly average number of (a) headache days of at least moderate severity, (b) migraine days, and (c) acute headache medication use during the 12-week treatment period with and without MO. CM, chronic migraine; LSM, least-squares mean; MO, medication overuse; SE, standard error